Overview

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S